#Imjudo

[amcrasto]

Tremelimumab

(Light chain)DIQMTQSPSS LSASVGDRVT ITCRASQSIN SYLDWYQQKP GKAPKLLIYA ASSLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSTPFTFGP GTKVEIKRTV AAPSVFIFPPSDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLTLSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC(Heavy chain)QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDP RGATLYYYYY GMDVWGQGTTVTVSSASTKG…

[drcare4u]

Imjudo Plus Imfinzi Improve Survival Versus Nexavar in Liver Cancer

A treatment combination of Imjudo (tremelimumab) and Imfinzi (durvalumab) demonstrated improved survival outcomes, including disease control and treatment responses in patients with unresectable (surgically unremovable) hepatocellular carcinoma (liver cancer), according to a presentation at the 2024 ESMO Congress. The presentation highlighted updated five-year data from the phase 3 HIMALAYA…

[biotech-news-feed]

Opinion/decision on a Paediatric investigation plan (PIP): Imjudo, Tremelimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0302/2023 #BioTech #science

[thunderrabby-blog]

AstraZeneca's Imjudo/Imfinzi combo gets approval in Japan for 3 cancer types

AstraZeneca’s Imjudo/Imfinzi combo gets approval in Japan for 3 cancer types

Roland Magnusson/iStock Editorial via Getty Images Japan’s Ministry of Health, Labour, and Welfare approved AstraZeneca’s (NASDAQ:AZN) immunotherapies Imfinzi and Imjudo to treat certain types of liver and lung cancers and Imfinzi to treat biliary tract and liver cancers. The approvals allow Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) to treat adult patients with unresectable…

[mintingprofit]

AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU

AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU

AstraZeneca PLC said Monday that its Imfinzi and Imjudo combinations have been recommended for marketing authorization in the European Union for advanced liver and lung cancer. The Anglo-Swedish pharma giant AZN, -0.39%   AZN, -2.58% said the Committee for Medicinal Products for Human Use of the European Medicines Agency based its opinion on results from the Himalaya Phase 3 trial, and results…